For example, in triple-negative breast cancer, gain of a superenhancer was detected at the BCLX locus and served as a mechanism of maintaining BCL-XL expression and resistance to JQ1 [143]. The gene discussed is BCL2L1; the disease is triple-negative breast carcinoma.